Clinical Trials Logo

Filter by:
NCT ID: NCT00641537 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

CLARITY Extension Study

Start date: February 29, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.

NCT ID: NCT00641056 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Start date: April 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic improvements, body weight, fasting lipids, safety, and tolerability.

NCT ID: NCT00640848 Completed - Insomnia Clinical Trials

Almorexant in Primary Insomnia

Insomnia
Start date: May 2006
Phase: Phase 1
Study type: Interventional

The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters.

NCT ID: NCT00640614 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

Start date: April 2008
Phase: Phase 3
Study type: Interventional

We propose an open, prospective, multi-center Phase III study to evaluate the diagnostic performance and safety of seven new T.R.U.E. Test allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol.Allergen performance and safety will be evaluated in adult patients with suspected contact dermatitis, and in adult patients with a known or suspected sensitization to at least one of the seven allergens.

NCT ID: NCT00640328 Completed - Multiple Sclerosis Clinical Trials

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

OMS115102
Start date: May 2008
Phase: Phase 2
Study type: Interventional

The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or Immunoglobulin G (IgG) levels.

NCT ID: NCT00640250 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

Start date: April 2008
Phase: Phase 2
Study type: Interventional

We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").

NCT ID: NCT00639808 Completed - Diabetes Mellitus Clinical Trials

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether TZP-101 is safe in people with diabetes. Also to determine if TZP-101 is effective in increasing the gastric emptying rate in diabetic patients.

NCT ID: NCT00639613 Completed - Type 2 Diabetes Clinical Trials

The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia

T2DM-PC1-2
Start date: March 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether excessive secretion of glucagon in type 2 diabetes originates from the pancreatic alpha-cells or endocrine cells in the mucosa of the small intestinal.

NCT ID: NCT00639054 Completed - Multiple Myeloma Clinical Trials

The Molecular Characterization of Multiple Myeloma at Relapse

MM-FISH/DNA
Start date: March 2008
Phase: N/A
Study type: Observational

Observational study investigating prognostic factors in newly diagnosed and relapsed multiple myeloma patients by use of clinical data, biochemical markers (blood samples), cytogenetic markers and gene expression profiling (myeloma cells from fresh bone marrow samples). Enabling future genetic studies by establishing a biobank of bone marrow and peripheral blood samples.

NCT ID: NCT00638742 Completed - Glaucoma Clinical Trials

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

Start date: May 2008
Phase: Phase 1
Study type: Interventional

To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.